Pcn94 Capecitabine + Oxaliplatin (Xelox) vs. 5-Fu/Lv + Oxaliplatin (Folfox4) in the Adjuvant Treatment of Patients With Colon Cancer (Acc): Comparison of Direct Medical and Societal (Indirect) Costs

Winterhalder, Ralph; Delmore, Geoffrey; Lier, Monique van; Urspruch, A.; Hieke, K

doi:10.1016/s1098-3015(11)71989-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The medical resources can be saved and the medical cost for colorectal cancer may decline as the result of decreased hospitalization stay. Moreover, Winterhalder reported Xelox is cost saving versus Folfox4, presenting the economic benefits of Xelox chemotherapy [ 37 ]. 3.…”

Section: Discussionmentioning

confidence: 99%

Fast track multi-discipline treatment (FTMDT trial) versus conventional treatment in colorectal cancer--the design of a prospective randomized controlled study

Zhou¹,

Li²,

Xiao³

et al. 2011

BMC Cancer

View full text Add to dashboard Cite

BackgroundLaparoscopy-assisted surgery, fast-track perioperative treatment are both increasingly used in colorectal cancer treatment, for their short-time benefits of enhanced recovery and short hospital stays. However, the benefits of the integration of the Laparoscopy-assisted surgery, fast-track perioperative treatment, and even with the Xelox chemotherapy, are still unknown. In this study, the three treatments integration is defined as "Fast Track Multi-Discipline Treatment Model" for colorectal cancer and this model extends the benefits to the whole treatment process of colorectal cancer. The main purpose of the study is to explore the feasibility of "Fast Track Multi-Discipline Treatment" model in treatment of colorectal cancer.MethodsThe trial is a prospective randomized controlled study with 2 × 2 balanced factorial design. Patients eligible for the study will be randomized to 4 groups: (I) Laparoscopic surgery with fast track perioperative treatment and Xelox chemotherapy; (II) Open surgery with fast track perioperative treatment and Xelox chemotherapy; (III) Laparoscopic surgery with conventional perioperative treatment and mFolfox6 chemotherapy; (IV) Open surgery with conventional perioperative treatment and mFolfox6 chemotherapy. The primary endpoint of this study is the hospital stays. The secondary endpoints are the quality of life, chemotherapy related adverse events, surgical complications and hospitalization costs. Totally, 340 patients will be enrolled with 85 patients in each group.ConclusionsThe study initiates a new treatment model "Fast Track Multi-Discipline Treatment" for colorectal cancer, and will provide feasibility evidence on the new model "Fast Track Multi-Discipline Treatment" for patients with colorectal cancer.Trial registrationClinicalTrials.gov: NCT01080547

show abstract

Section: Discussionmentioning

confidence: 99%